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Urokinase-type plasminogen activator receptor (uPAR) plays a central role in the plasminogen activation cascade and participates in
extracellular matrix degradation, cell migration and invasion. We evaluated the expression level of uPAR mRNA and the presence of
isolated tumour cells (ITCs) in bone marrow (BM) and peripheral blood (PB) in gastric cancer patients and clarified its clinical
significance. We assessed specific uPAR mRNA expression by quantitative real-time reverse transcriptase- polymerase chain reaction
(RT–PCR) in BM and PB in 846 gastric cancer patients as well as three epithelial cell markers, carcinoembryonic antigen (CEA),
cytokeratin (CK)-19 and CK-7. The uPAR mRNA expression in bone marrow and peripheral blood expressed significantly higher than
normal controls (Po0.0001). The uPAR mRNA in BM showed concordant expression with the depth of tumour invasion, distant
metastasis, and the postoperative recurrence (P¼0.015, 0.044 and 0.010, respectively); whereas in PB, we observed more intimate
significant association between uPAR expression and clinicopathologic variables, such as depth of tumour invasion, the distant
metastasis, the venous invasion and the clinical stage (P¼0.009, 0.002, 0.039 and 0.008, respectively). In addition, the uPAR mRNA
expression in PB was an independent prognostic factor for distant metastasis by multivariate analysis. We disclosed that it was
possible to identify high-risk patients for distant metastasis by measuring uPAR mRNA especially in peripheral blood at the timing of
operation in gastric cancer patients.
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The presence of isolated tumour cells (ITCs) in bone marrow (BM)
and peripheral blood (PB) is missed by conventional imaging
system, and ITCs expected to be a determinant factor of
subsequent formation of micrometastasis. The search for ITCs in
patients with curatively resected tumours is of considerable
importance, because early dissemination of tumour cells is one
of the leading causes of relapse at the distant site and of death from
cancer (Hellman, 1997). In spite of large number of studies to
determine the clinicopathologic significance of ITCs in human
solid carcinomas, much efforts have been made and found no
definitive evidence to conclude these controversial issues, such as
the way to identify ITCs and the appropriate biologic marker to
predict the metastatic ability of gastric cancer cells (Heiss et al,
1995, 1997, 2002; Jauch et al, 1996; Hardingham et al, 2000;
Lecomte et al, 2002; Natsugoe et al, 2003; Ikeguchi and Kaibara,
2005).
To identify ITCs in BM or PB, a bunch of molecular targets, such
as CEA, CK7, CK18, CK18, CK19 and MAGE families have been
applied and examined whether those genes were applicable to
detect ITCs. Above all candidates, CEA and cytokeratin (CK),
epithelial cell surface markers were frequently used to be applied
to detect ITCs instead of the direct detection of cancer cells in
those ITC studies. However, our recent study disclosed that ITCs
in BM and PB from gastric cancer could not be specified by the
presence of CEA and/or CKs by RT–PCR, because those genes
were detected ubiquitously among stages of 810 patients of gastric
cancer. Therefore, we must identify a favourite marker to detect
ITCs specifically as well as to predict metastasis precisely. In the
current study, we focused on urokinase-type plasminogen
activator receptor (uPAR) gene as a target molecule to detect
isolated tumour cells in blood and bone marrow. This is because
that in gastric cancer, several reports showed clearly that uPAR
expression in bone marrow (BM) is one of the useful prognostic
marker by immunohistochemistry (Heiss et al, 1995, 2002;
Allgayer et al, 1997). However, there are no earlier reports of the
clinical significance of the gene expression level of uPAR with
quantitative RT–PCR assay that enabled us to examine objectively
and repeatedly. Therefore, the aim of the current study was to
evaluate the expressions of uPAR mRNA in bone marrow and
peripheral blood in more than 800 cases of gastric cancer and to
define its clinicopathologic and prognostic significance in gastric
cancer patients.
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Gastric cancer cases
A total of 846 gastric cancer patients who underwent surgical
treatment in the National Cancer Center Hospital, Japan from 2001
to 2004 were studied. Clinical stages and pathological features of
primary tumours were defined according to the classification of
the International Union Against Cancer (Sobin and Fleming, 1997).
There were 567 male and 279 female patients with average age 61.5,
and a range of 27–87 years. None of these patients underwent
endoscopic mucosal resection or palliative resection. Written
informed consent had been obtained from all patients.
Normal controls
For normal negative controls, both peripheral blood and bone
marrow were collected from 25 patients having no malignancy
from April 2000 to March 2003. This group included 16 cases of
gallstone, three cases of common bile duct stone, and six cases
of incisional hernia. We extracted BM from the sternum of
patients without malignancies but had operations under general
anaesthesia.
Bone marrow and blood samples
Aspiration of both BM and PB was conducted immediately prior to
operation under general anaesthesia. The aspirated BM was
obtained from the sternum using a bone marrow aspiration needle
(MDTECH, Gainesville, FL, USA). Peripheral blood was obtained
through a venous catheter. The 1ml of both BM and PB samples
was discarded to avoid the contamination of the epidermal cells
(Iinuma et al, 2006). Each 1ml sample of BM and PB was
immediately mixed with 4ml of ISOGEN-LS (Nippon Gene,
Toyama, Japan) and stored at  801C until RNA extraction.
Total RNA extraction and first strand cDNA synthesis
Total RNA was according to the ISOGEN-LS manufacturer’s
protocols. All the clinical samples obtained in National Cancer
Center Hospital were sent to our institute. The reverse transcrip-
tase reaction (RT) was performed as described earlier (Mori et al,
1995; Masuda et al, 2002). The first strand cDNA was synthesized
from 2.7mg of total RNA in a 30ml reaction mixture containing 5ml
5  RT reaction buffer (BRL, Gaithersburg, MD, USA), 200mM
dNTP, 100mM solution of random hexadeoxynucleotide mixture,
50 units of Rnasin (Promega, Madison, WI, USA), 2ml of 0.1 M
dithiothreitol, and 100U of Molony leukaemia virus RT (BRL). The
mixture was incubated at 371C for 60min, heated to 951C for
10min, and then chilled on ice.
Primers and probes for detecting ITCs and uPAR
expression
Quantitative RT–PCR methodology was designed to optimise the
specificity and fidelity of the assay. The Kyushu University group
had previously investigated the expression of seven representative
molecular markers (carcinoembryonic antigen (CEA), CK-7, CK-
18, CK-19, CK-20, mammaglobin and mucin (MUC)-1) in 27
cancers and eight non-epithelial cell lines using quantitative
RT–PCR. The expression levels of CK-7 and CK-19 showed high
sensitivity and specificity for the identification of gastric cancer
cells in comparison with the other markers (Masuda et al, 2005).
Those epithelial cell markers have been widely used as target genes
for the detection of ITCs (Mori et al, 1996, 1998; Yamaguchi et al,
2000; Bessa et al, 2003; Sadahiro et al, 2005). Thus, CEA, CK-7,
CK-19 and GAPDH were studied by quantitative RT–PCR in all
846 patients (Mimori et al, 2008). Isolated tumour cells were
considered to be ‘present’ when any single marker was positive.
The reverse transcriptase reaction was performed as described
elsewhere (Mimori et al, 2008). We performed real-time
quantitative RT–PCR using a LightCycler instrument (Roche
Diagnostics, Manheim, Germany) to detect ITCs in peripheral
blood and/or bone marrow as the previous study.
Moreover, a uPAR-specific oligonucleotide primer was designed
as follows: sense, 50-TGAATCAATGTCTGGTAGC-30 and antisense,
50-TGGTTACAGCCACTTTTAGT-30. The donor and acceptor
probe sequences for uPAR identification were 50-GCTATATGGTA
AGAGGCTGTGCAACCGCCT-fluorescein and 50-LC-Red640-AAT
GTGCCAACATGCCCACCTGGG T -phosphorylation. Besides, uPA
primers were as follows: forward primer; CTGTGACTGTC
TAAATGGAGG; and the reverse primer; GACGATGTAGTCCT
CCTTCTT (Nielsen et al, 2004).
Preliminary trials were undertaken to assure that results were
accurate and reliable. We utilised highly specific hybridisation
probes and primers to maintain high specificity for target genes
and thereby reduce false positive outcomes.
RT–PCR conditions
PCR amplification was performed using a quantitative fluores-
cence LightCyclert (Roche Diagnostics, Mannheim, Germany) in a
20ml reaction mixture containing 2ml of LightCyclert FastStart
DNA Master Hybridisation Probes (Roche, Diagnostics, Tokyo,
Japan), 4.0ml MgCl2, 0.3mM sense and antisense primers, 0.2mM
fluorescent probe, 0.2mM LC-Red probe and 5ml of undiluted
template cDNA in LightCyclert capillaries (Roche Diagnostics,
Tokyo, Japan). The amplification of CEA profile consisted of one
cycle at 951C for 10min (denaturation) followed by 45 cycles of
951C for 15s, 561C for 15s and 721C for 13s. The amplification of
CK-7 profile consisted of one cycle at 951C for 10min (denatura-
tion) followed by 50 cycles of 951C for 10s, 601C for 12s and 721C
for 10s. The amplification of CK-19 profile consisted of one cycle
at 951C for 10min (denaturation) followed by 45 cycles of 951C for
10s, 601C for 15s and 721C for 16s. The amplification of uPAR
profile consisted of one cycle at 951C for 10min (denaturation)
followed by 40 cycles of 951C for 10s, 621C for 15s and 721C for
8s. The amplification of GAPDH profile consisted of one cycle at
951C for 10min (denaturation) followed by 40 cycles of 951C for
15s, 601C for 15s and 721C for 13s. The amplification of uPA was
as follows: 5min at 941C, 27 cycles of 1min at 941C, 1min at 561C,
1min at 721C, then 10min at 721C (Nielsen et al, 2004). Real-time
PCR was monitored by measuring fluorescent signals at the end of
the annealing phase for each cycle. All primers and probes were
synthesized and purified by reverse phase high-performance liquid
chromatography and the optimal reagent concentrations and PCR
cycling conditions were established and each run of RT–PCR
included positive controls synthesized from plasmids by the
Nippon Gene Research Laboratories (Sendai, Japan). Real-time
RT–PCR assays were repeated in triplicate and adapted the mean
value. Quantification data were analysed using the Light-Cyclert
software (Roche Diagnostics, Tokyo, Japan).
Data analysis
A standard curve was prepared with 200–20000 copies of purified
plasmids containing CEA, CK-7, CK-19, uPAR and GAPDH. After
proportional baseline adjustment, the fit point method was
employed to determine the cycle in which the log-linear signal
was first distinguishable from the baseline, and then that cycle
number was used as a crossing-point value (Marutsuka et al,
2003). The standard curve was produced by measuring the
crossing point of each standard value and plotting them against
the logarithmic value of concentrations. Those concentrations
were calculated by plotting their crossing points against the
standard curve.
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case for GAPDH expression. We set cutoff values for those
expression ratios (CEA/GAPDH, CK-7/GAPDH, CK-19/GAPDH,
uPAR/GAPDH) as the highest value for each marker in 25 normal
controls. We distributed high level as ‘positive’ and low level as
‘negative’ than the cutoff value. For continuous variables, the data
were expressed as the mean±s.d. Statistical analysis of group
differences was performed using the w
2 test and the Student’s t-test.
Logistic regression model was used to identify the independent
predictors of distant metastasis. All tests were analysed using JMP
software (SAS Institute Inc., Cary, NC, USA). Statistical significance
was determined as P-value from two-sided tests of less than 0.05.
RESULTS
Expression of uPAR mRNA in BM and PB of gastric cancer
patients
In BM, the value of the uPAR expression of gastric cancer patients
(6.0±0.24 ( 10
 3)) was significantly higher (Po0.0001) than
those of control cases (9.94±0.93 ( 10
 4)), as shown in Figure 1.
In PB, the value of the uPAR expression of gastric cancer patients
(1.49±0.11 ( 10
 2)) was also significantly higher (Po0.0001)
than those of control cases (1.57±0.66 ( 10
 3)).
Clinical magnitude of uPAR expression in gastric cancer
patients
The correlations between the results for the uPAR mRNA level and
clinicopathologic factors are summarised in Table 1. Using each
cutoff value, 431 (50.9%) and 404 (47.8%) of 846 patients were
estimated to be positive for uPAR mRNA in BM and PB, respectively.
In BM, the significantly higher population of the uPAR mRNA-
positive cases belongs to the following clinical subgroups: invasion
deeper than the muscularis propria (P¼0.015), perioperative overt
metastases (including liver and/or lung and/or distant lymph node
metastasis, P¼0.044) and postoperative recurrence (P¼0.010).
In PB, the higher expression was observed significantly in
subgroup invasion deeper than the muscularis propria (P¼0.009),
perioperative overt metastases (P¼0.002), venous invasion
(P¼0.039), and the clinical stage (P¼0.008).
Multivariate analysis for distant metastasis
Univariate and multivariate logistic regression analyses were
performed on cases with distant metastasis (Table 2). Univariate
regression analysis showed that the following factors were
significantly associated with distant metastasis: histological grade,
tumour size, lymph node metastasis, lymphatic invasion, venous
invasion and uPAR mRNA expressions in BM and PB (Po0.05),
respectively. Multivariate regression analysis indicated that uPAR
mRNA high expression group in PB (relative risk (RR); 1.85, 95 %
confidence interval (CI); 1.08–3.23, P¼0.03) was an independent
predictor for distant metastasis next to the incidence lymph node
metastasis (RR; 6.50, 95 % CI; 2.99–15.77, Po0.0001) and depth of
tumour invasion (RR; 28.2, 95% CI; 14.3–70.0, Po0.0001).
The comparison of uPA and uPAR expression in
representative gastric cancer cases
The potential importance of uPAR for the development of minimal
residual disease in solid cancer has been focused on for recent two
decades; however, several studies revealed that the relevance of a
ligand for uPAR, uPA in mediating tumour-associated proteolysis,
invasion and metastasis together with uPAR expression (Andreasen
et al, 2000). We examined uPA expression in bone marrow and
peripheral blood in representative 83 cases of gastric cancer,
including 18 cases of liver and/or lung metastasis, and 12 cases of
recurrence of disease among 846 cases of gastric cancer. As we
showed in Table 3, we found that uPA expression in bone marrow
from gastric cancer is correlated with the incidence of lymph node
metastasis and recurrence of gastric cancer cases as uPAR expression.
The clinical significance of both positive ITCs and positive
uPAR expression
We identified 66 cases out of 846 (7.8%) that were positive for
expression of CEA in bone marrow, whereas 108 (12.7%) were
positive in peripheral blood. As for CK-7, 71 patients (8.4%) and
147 cases (20.6%) were positive in bone marrow and in peripheral
blood, respectively. Cytokeratin-19 expression was detected in
bone marrow in 153 cases (18.1%) and in 251 cases (29.7%) in
peripheral blood. Gastric cancer cases with positive expression of
any one of the three markers were defined as ITC-positive in bone
marrow or peripheral blood. As outlined above, ITCs were
detected in 260 (30.7%) cases in bone marrow and 417 (49.3%)
cases in peripheral blood.
Moreover, we extracted 126 cases (14.9%) in BM and 200 cases
(23.6%) in PB of positive ITCs and positive uPAR expression cases.
Table 4 shows the clinicopathologic data and positive ITCs and
positive uPAR cases from the 846 gastric cancer patients. In BM,
the incidence of lymph node metastasis was significantly higher
(P¼0.012) in the both positive group (65 of 126, 51.6%) than in
the other group (285 of 720, 39.6%), and the incidence of
lymphatic invasion was significantly higher (P¼0.009) in the
both positive group (67 of 126, 53.2%) than in the other group (293
of 720, 40.7%). Moreover, the clinical stage was significantly higher
(P¼0.024) in the both positive group (42 of 126, 33.3%) than in
the other group (170 of 720, 23.4%). In PB, there was no
significance between the both positive group and the other group.
DISCUSSION
In this study, we examined the clinicopathologic significance of
uPAR expression in BM and PB in 846 cases of gastric cancer, and
found that the depth of tumour invasiveness in the primary
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Figure 1 Comparison of uPAR mRNA expression between control
gastric cancer patients in bone marrow (A) and peripheral blood (B).
Horizontal lines indicate the mean expression levels in control and gastric
cancer patients. In bone marrow and peripheral blood, the value of the
uPAR expression of gastric cancer patients was significantly higher
(Po0.0001) than those of control cases. The P-value was calculated by a
student’s t-test.
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stumour was significantly higher in cases of uPAR (þ) in BM and/
or PB than uPAR( ) cases. In addition, we disclosed an evidence
of the concordant relationship between the venous permeation in
primary cancer and the incidence of uPAR expression. In spite of
the strong association between tumour invasiveness, the presence
of uPAR in PB was uncovered to be much more intimate to the
incidence of metastasis and could be an independent prognostic
indicator for hematogenous metastasis. Therefore, we consider
that uPAR might play a consecutive role in cancer cells to invade
into vessels and/or invading into the metastatic site. Furthermore,
the clinical relevance of uPAR in bone marrow was observed with
the incidence of recurrence, not with the synchronous distant
metastasis. There was a possible explanation which is as follows,
Kook et al (1994) reported that uPAR can play a role in tumour cell
dormancy. They reported that a uPAR-antisense strategy in a
human squamous carcinoma cell line resulting in a significant
reduction of uPAR gene expression, induced tumour cell
dormancy in their study. Besides, Laufs et al (2006) described
this point in the review concerning uPAR. Therefore, the abundant
expression of uPAR in bone marrow might indicate the presence of
many dormant cells giving rise to recurrence in the future.
In an earlier study by Jauch et al (1996) uPAR is a glycosyl-
phosphatidylinositol-anchored glycoprotein localised on the outer
layer of the plasma membrane of cells, and it binds to its
specific ligands such as urokinase-type plasminogen activator
(uPA). In this study, we confirmed the concordant relationship
between uPAR and uPA in bone marrow and peripheral
blood indicating that both proteins have a synergistic role with
each other in lymph node metastasis and recurrence of gastric
cancer. However, uPAR activation ultimately leads to degradation
of the extracellular matrix and fascinates cellular movement
for tumour cells, which appears to be necessary for diverse
Table 2 Univariate and multivariate analysis for distant metastasis (logistic regression model)
Univariate analysis Multivariate analysis
RR 95% CI P-value RR 96% CI P-value
Histological grade (Differentiated/undifferentiated) 2.35 1.31–2.35 o0.0001 0.58 0.24–1.45 0.239
pT (Depth of tumour invasion) 49.91 27.36–99.07 o0.0001 28.17 14.30–60.95 o0.0001
pN (Lymph node metastasis) 22.78 11.56–51.49 o0.0001 6.5 2.99–15.77 o0.0001
Lymphatic invasion 12.12 6.89–23.12 o0.0001 — — —
Venous invasion 4.55 2.91–7.10 o0.0001 1.61 0.90–2.88 0.106
uPAR mRNA expression in bone marrow 1.53 1.01–2.35 0.046 — — —
uPAR mRNA expression in peripheral blood 1.95 1.28–2.99 0.002 1.85 1.08–3.23 0.0207
Table 1 Relationship between uPAR expression in bone marrow and peripheral blood and clinicopathologic findings
uPAR expression in bone marrow uPAR expression in peripheral blood
Positive Negative Positive Negative
Total 846 n¼431 (50.9%) n¼415 (49.1%) P-value n¼404 (47.8%) n¼442 (52.2%) P-value
Age (mean±s.d.
a) 60.4±0.55 62.7±0.56 NS 61.5±0.57 61.6±0.55 NS
Gender 0.233 0.688
Male 567 297 (69.1) 270 (65.2) 268 (66.5) 299 (67.8)
Female 279 134 (30.9) 145 (34.8) 136 (33.5) 143 (32.2)
Histology 0.127 0.174
Differentiated 188 105 (24.4) 83 (20.0) 98 (24.3) 90 (20.4)
Undifferentiated 658 326 (75.6) 332 (80.0) 306 (75.7) 352 (79.6)
pT 0.015 0.009
pT1/T2 657 320 (74.3) 337 (81.2) 298 (73.8) 359 (81.2)
pT3/T4 189 111 (25.7) 78 (18.8) 106 (26.2) 83 (18.8)
pN 0.707 0.072
pN0 496 250 (58.0) 246 (59.3) 224 (55.5) 272 (61.5)
pN1 350 181 (42.0) 169 (40.7) 180 (44.5) 170 (38.5)
pM (Distant metastasis
a) 0.044 0.002
pM0 743 369 (85.6) 374 (90.1) 340 (84.2) 403 (91.2)
pM1 103 62 (14.4) 41 (9.9) 64 (15.8) 39 (8.8)
Postoperative recurrence 0.01 0.115
Non recurrence 833 420 (97.5) 413 (99.5) 395 (97.8) 438 (99.1)
Recurrence 13 11 (2.5) 2 (0.5) 9 (2.2) 4 (0.9)
Lymphatic invasion 0.617 0.16
Negative 486 244 (58.3) 242 (58.3) 222 (55.0) 264 (59.7)
Positive 360 187 (56.6) 173 (41.7) 182 (45.0) 178 (40.3)
Venous invasion 0.425 0.039
Negative 702 362 (83.9) 340 (81.9) 324 (80.2) 378 (85.5)
Positive 144 69 (16.1) 75 (18.1) 80 (19.8) 64 (14.5)
Stage 0.081 0.008
I, II 634 312 (72.4) 322 (77.6) 286 (70.8) 348 (78.7)
III, IV 212 119 (27.6) 93 (22.4) 118 (29.2) 94 (21.3)
aGastric cancer case with liver (H1) and/or lung metastasis (M1), cytology positive of peritoneal washes (CY1), peritoneal dissemination (P), and lymph node metastasis in the
distant region (N3).
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(Heiss et al, 1997).
Then, the second point is what is the origin of cells expressing
uPAR gene in BM and especially in PB. As a matter of fact, Heiss
et al (1995, 1997, 2002) reported that the gastric cancer patients
with cells with uPAR protein expression by immunocytology
showed significantly poorer prognosis than cases without uPAR
expression by Kaplan–Meier analysis in the previous study (Jauch
et al, 1996; Hardingham et al, 2000). They confirmed that uPAR
protein expressing cells on the surface cells was a cancer cell by
immunocytological study. Their study strongly supported the
current study by quantitative RT–PCR assay that the detected
uPAR expression by RT–PCR should be originally from gastric
cancer cells, and gastric cancer patients with cancer cells with the
invasive ability especially in PB. Moreover, we additionally
disclosed that cancer patients with simultaneous expression uPAR
and epithelial cell markers, CEA, CK19 and CK7 showed a relatively
poorer prognosis than ITCs alone. Gastric cancer cell isolated from
primary cancer is circulating in the peripheral blood and bone
marrow ubiquitously among whole stages (Mimori et al, 2008);
however, isolated cancer cells with several potential abilities must
be required to form metastasis. According to this study, we
concluded that uPAR-expressing isolated tumour cells are
important in the determination of recurrence through lymph
node metastasis.
On the contrary to the hypothesis of the origin of uPAR
expression in cancer cells, several studies have uncovered findings
of the uPAR from host side cells in BM or PB from cancer patients.
Pyke et al (1993) reported the abundant expression of uPAR in
macrophage (Dubuisson et al, 2000), and Sugai et al (2004)
disclosed that advances in gastric cancer cases indicated the
activation of inflammatory cytokines, such as IL-10 and IL-12 from
macrophages. Furthermore, Hildenbrand et al (1998) mentioned
that the abundant expression of uPAR was observed in endothelial
cells, which has been recently really focused on as the key player
for the initial development of metastasis. Mancuso et al (2001)
reported that the number of circulating endothelial cells (CECs) in
PB from cancer patients are more than that in healthy volunteers
(Beerepoot et al, 2004). Asahara et al (1997) reported that bone
marrow-derived endothelial cell progenitor cells were dissemi-
nated to the neovascularisation of the cellular surface of malignant
cells (Peters et al, 2005). In addition, EPC-specific gene, Id-1, was
reported to be identified and its consecutive role for metastasis has
been reported in the recent study. Therefore, we considered that
the presence of CEC or EPC in PB should be important to form
metastasis, and our current study elucidated the role of uPAR
especially in PB as the independent marker for metastasis.
In this study, we concluded that the RT–PCR assay for uPAR
expression in PB can be one of the favourite tumour markers to
predict DFS in gastric cancer outpatients. Then, we disclosed the
abundant expression of uPAR in gastric cancer cases with invasion
and with venous invasion abilities. Earlier Heiss et al distinctively
disclosed that uPAR expression in BM and PB in gastric cancer is
originally from cancer cells themselves (Heiss et al, 1995).
However, as the clinicopathologic significance and the predictive
role for metastasis is much more consecutive in uPAR in PB than
in BM, uPAR might be originally expressed in endothelial
(progenitor) cells as the host side reaction in gastric cancer
patients. Further study will be required to address this con-
troversial issue.
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P NS NS NS NS
  80 9.5E-03 7.9E-03 1.3E-02 8.4E-03 2.1E-02 1.5E-02 2.6E-03 4.5E-03
+ 8 1.3E-02 9.4E-03 1.4E-02 7.6E-03 2.6E-02 1.6E-02 2.7E-03 1.9E-03
met NS NS NS 0.0265
  70 9.2E-03 7.9E-03 1.3E-02 8.2E-03 2.0E-02 1.3E-02 2.1E-03 1.9E-03
+ 18 1.2E-02 8.7E-03 1.6E-02 8.4E-03 2.8E-02 1.9E-02 4.6E-03 8.7E-03
rec 0.0072 NS 0.0409 NS
  76 8.9E-03 6.6E-03 1.4E-02 8.6E-03 2.0E-02 1.5E-02 2.6E-03 4.6E-03
+ 12 1.6E-02 1.3E-02 1.1E-02 5.9E-03 3.0E-02 1.3E-02 2.2E-03 1.5E-03
cy¼cytology of peritoneal washes; ly¼lymphatic permiation; met¼liver and/or lung metastasis; n¼lymph node metastasis; p¼peritoneal dissemination; rec¼recurrence;
s.d.¼standard deviation; v¼vascular permiation. Significant differences (Po0.05) were described in bold letters.
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